Kintiga UK & Ireland
Navigate the complex pathway to patients with ease
Kintiga UK & Ireland
We are a team of bold, dynamic thinkers with deep expertise in pharmaceutical market access, regulatory affairs, medical and scientific strategy, and public policy. Rooted in local expertise and driven by global collaboration, we empower health technology developers to deliver impactful therapies to patients across Europe.
Our approach combines agility with precision, guiding you through the complexities of European patient access with confidence and clarity.
BeNeLux Insights
Our expertise:
UK and Ireland Access Consultancy
Our UK and Ireland team provide tailored strategic guidance and end-to-end support across development, launch, and lifecycle management, aligned with NICE, SMC, AWMSG, and NCPE pathways and evolving HTA expectations.
UK and Ireland Market Access Pathways
Success starts with a clear launch pathway. Kintiga offers UK and Ireland expertise, supporting NICE, SMC, AWMSG, and NCPE submissions with strong evidence alignment, payer negotiation, and stakeholder engagement to drive positive outcomes.
EU HTA Strategy Support
With extensive NICE submission experience, Kintiga is well positioned to support Joint Clinical Assessments, offering integrated solutions from JSC advice to JCA reporting for successful EU HTA outcomes.
Health Economics and Outcomes Research
Our Health Economists build and adapt economic models for the UK and Ireland, integrating local data, comparators, and care pathways. We also develop early pricing and access models to guide investment and evidence strategies aligned with payer expectations.
Pricing Strategy
Kintiga analyses pricing landscapes and benchmarks competitors to shape early pricing strategies. We integrate value messaging and design long-term frameworks like risk-sharing and managed entry agreements to ensure sustainable UK and Ireland market access.
Policy and Systems Navigation
Kintiga monitors policy changes across NHSE, DoH, HSE, and regional bodies to assess their impact on your product. We provide strategic engagement with key institutions and support managed access, conditional reimbursement, and policy initiatives to optimise market entry and sustainability.
UK & Ireland Insights
Delivering a Successful SMC Re‑Submission Through Strategic Alignment and Rapid Cross‑Functional Execution
Faster, Fairer, Broader: What NICE’s 2025–26 Annual Report Means for Market Access
NICE’s New Rulebook for Obesity Health Economics: What PMG50 Means for Modellers
PMI Pharma Summit
NICE Conference 2026
Poster Presentation: Increased trends of self-optimised submissions to NICE (HTA 199)
Our products
Navigate evolving regulations and market demands confidently with up-to-date insights and guidance from Kintiga’s innovative AI-powered digital tools.
Hive by Kintiga
Access the collective expertise of our consultants and the insights and strategic guidance to simplify approvals across Europe’s healthcare any time and from anywhere.
EPRI
EPRI (EndPoint Result Interpreter) is a cutting-edge AI solution designed to streamline the creation of tailored, high-quality dossiers.
Get in touch with our team now
Contact us to discover how we can support your journey towards pharmaceutical market access & patient access.
